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Abstract
Introduction: AIDS-related deaths in people living with HIV/AIDS have been decreasing in number since the introduction of
combination antiretroviral treatment (cART). However, data on recent causes of death in the Asia-Pacific region are limited.
Hence, we analysed and compared AIDS-related and non-AIDS–related mortality in high- and low-income settings in the
region.
Methods: Patients from the TREAT Asia HIV Observational Database (TAHOD) and Australian HIV Observational Database
(AHOD) receiving cART between 1999 and 2017 were included. Causes of death verification were based on review of the
standardized Cause of Death (CoDe) form designed by the D:A:D group. Cohorts were grouped as AHOD (all high-income
sites), TAHOD-high (high/upper-middle income countries) and TAHOD-low (lower-middle income countries). TAHOD sites
were split into high/upper-middle income and lower-middle income country settings based on World Bank classifications. Com-
peting risk regression was used to analyse factors associated with AIDS and non-AIDS–related mortality.
Results: Of 10,386 patients, 522 died; 187 from AIDS-related and 335 from non-AIDS–related causes. The overall incidence
rate of deaths during follow-up was 0.28 per 100 person-years (/100 PYS) for AIDS and 0.51/100 PYS for non-AIDS. Analysis
indicated that the incidence rate of non-AIDS mortality decreased from 0.78/100 PYS to 0.37/100 PYS from year groups
2003 to 2007 to 2013 to 2017 (p < 0.001). Similarly, incidence rates of AIDS-related deaths decreased from 0.51/100 PYS
to 0.09/100 PYS from year groups 2003 to 2007 to 2013 to 2017 (p < 0.001). More recent years of follow-up were associ-
ated with reduced hazard for non-AIDS mortality (2008 to 2012: aSHR (adjusted sub-hazard ratio) 0.72, 95% confidence
interval (CI) 0.54 to 0.96, p = 0.027; 2013 to 2017: aSHR 0.64, 95% CI 0.47 to 0.87, p = 0.004) compared to years 2003 to
2007. The AHOD cohort had almost twice the hazard of non-AIDS mortality compared to TAHOD-low (lower-middle income
sites) (aSHR 1.72, 95% CI, 1.20 to 2.46, p = 0.003); there were no differences between cohorts for AIDS-related mortality
(p = 0.834).
Conclusion: AIDS and non-AIDS–related mortality rates have decreased over the past years in the Asia-Pacific region. There
is a greater risk for non-AIDS–associated deaths in the AHOD cohort compared to lower-middle income settings in TAHOD.
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1 | INTRODUCTION
Since the introduction of combination antiretroviral treatment
(cART), the incidence and major causes of death among indi-
viduals with HIV infection have changed substantially [1-4].
Compared to the pre-cART era, there has been a decrease in
death rates attributable to AIDS itself and an increasing
proportion of deaths related to non-AIDS causes [1,5]. The
incidence of AIDS-defining cancers decreased and the inci-
dence of non-AIDS-defining cancers increased after the intro-
duction of cART, due to better viral replication control and
increased immunity, which led to longer lifespans and there-
fore an increased chance of developing comorbidities that are
more common with age, such as most non-AIDS–defining
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cancers [5]. According to the Data collection on Adverse
events of anti-HIV Drugs (D:A:D) study, trends over time in
all-cause mortality in people with HIV demonstrated a
decrease in AIDS-related death rates [1]. Moreover, the pro-
portion of non-AIDS cancers increased from 9% in 1999 to
2000 to 23% in 2009 to 2011 [1]. A Swiss HIV cohort study
demonstrated similar results with 84% of deaths between
2005 and 2009 due to non-AIDS–related causes [6]. Improve-
ment in CD4 cell count was accountable for the recent reduc-
tions in rates of AIDS-related deaths [1].
A previous study conducted in the Asia-Pacific region exam-
ined factors predictive of AIDS-related and non-AIDS–related
mortality, as well as the cumulative incidences of each cause
of death before the year 2007: 215 deaths (89 from AIDS, 97
from non-AIDS and 29 unknown) were identified, immune
deficiency defined by lower CD4 cell counts was predictive of
increased risk of AIDS-related and non-AIDS–related deaths,
and older age (≥50 years) predicted non-AIDS mortality [7].
Other studies in the region have identified risk factors for
developing AIDS-defining cancers [8,9].
We hypothesize that the causes of AIDS-related and non-
AIDS–related mortality have changed over the past decade as
HIV treatment programs in the Asia-Pacific region have
matured, and that rates of AIDS mortality have decreased, fol-
lowed by a relative increase in non-AIDS–related mortality.
The objective of this study was to investigate the incidence
rates of AIDS-related and non-AIDS–related deaths, and iden-
tify factors associated with different causes of death (COD)
across country income levels in the Asia-Pacific region during
the cART era.
2 | METHODS
2.1 | Study population and definitions
This analysis includes both Australian HIV Observational Data-
base (Australian HIV Observational Database) and the TREAT
Asia HIV Observational Database (TAHOD) enrolled patients
who started cART and attended at least one subsequent fol-
low-up visit. The AHOD and TAHOD are observational clinical
cohort studies of patients with HIV infection in Australia and
New Zealand (AHOD) and 12 countries (Cambodia, China and
Hong Kong SAR, India, Indonesia, Japan, Malaysia, the Philip-
pines, Singapore, South Korea, Taiwan, Thailand, and Vietnam)
in Asia and the Pacific region (TAHOD), whose methods have
previously been described [7-9].
The start date (baseline) for cART was defined as the date
patients started their first triple regimen. Those who used
mono/dual therapy prior to starting cART were excluded.
Cohorts were grouped as AHOD (all high-income sites),
TAHOD-high (high/upper-middle income countries) and
TAHOD-low (lower-middle income countries). TAHOD sites
were split into high/upper-middle income and lower-middle
income settings (there are no low-income sites in TAHOD)
based on World Bank classifications [10]. Deaths were classi-
fied as AIDS-related where the death was a direct conse-
quence of any AIDS-defining condition (as defined by the
Centers for Disease Control and Prevention [11]). Non-AIDS
deaths were further classified as being related to cardiovascu-
lar disease, liver disease, cancer, accidental/overdose/violence,
infectious disease, other and unknown [1]. Causes of death
were based on review of the standardized Cause of Death
(CoDe) form designed by the D:A:D group [12].
2.2 | Statistical analysis
2.2.1 | Proportions and incidence rates of
AIDS-related and non-AIDS–related mortality
Proportions of AIDS-related and non-AIDS–related mortality
were analysed descriptively. Calendar years were categorized
into ≤2007, 2008 to 2012 and 2013 to 2017. The denomina-
tor used to calculate each proportion was the total number of
deaths in each year group. Mortality rates for different causes
of deaths were also examined. The proportions and mortality
rates were plotted across calendar years of follow-up.
Unknown causes of death were plotted as a separate group
to allow for visual inspection of the reported cases of non-
AIDS causes of death.
2.2.2 | Factors associated with AIDS-related and
non-AIDS–related mortality
Fine and Grays’ competing risk regression model was used to
analyse factors associated with AIDS-related and non-AIDS–
related mortality. The resulting sub-hazard ratio (SHR) can be
interpreted in a similar way to the hazard ratio. Follow-up time
began from cART initiation and left truncated at cohort entry
for those who entered the cohort after starting cART. Left trun-
cation minimizes survival bias by taking into account survival
time prior to cohort entry in those who had initiated cART
before enrolment into the cohort. The earliest year of follow-up
started in 1999 for AHOD and 2002 for TAHOD. While follow-
up time ended at date of death for patients who experienced
mortality, all other patients were censored on their date of last
follow-up. Both AHOD and TAHOD cohorts had their last
follow-up date in year 2017. Other causes of death and loss to
follow-up (LTFU) [13-15] were defined as competing events.
Time-fixed covariates were age, sex, HIV mode of exposure, and
cohort groups. Patients were considered hepatitis B virus
(HBV) or hepatitis C virus (HCV) positive if they were ever
tested positive for HBV surface antigen or positive for HCV
antibody respectively. Covariates which varied with time were
diabetes, hypertension, body mass index (BMI), HIV RNA, CD4
cell count and calendar year (≤2002, 2003 to 2007, 2008 to
2012, and 2013 to 2017). These variables were time-updated
from risk time which began at antiretroviral treatment (ART)
initiation or cohort entry for those who had initiated cART prior
to cohort entry, till the date of last follow-up for those who
were alive and date of death for those who experienced mortal-
ity. Time-updated variables contribute different risk time in dif-
ferent categories. The missing category in the time-updated
variables refers to missing baseline values or patients who
never had a test in the entire follow-up time. Diabetes was
defined as documentation of one fasting blood glucose mea-
surement ≥7 mmol/L. Hypertension was not included as blood
pressure was not recorded by the AHOD cohort. BMI was
defined as underweight (<18.5), normal range (18.5 to 24.9)
and overweight (≥25). LTFU was defined as not having been
seen in clinic for >12 months without evidence of transfer.
With the exception of cohort groups, covariates in the uni-
variate analysis with p < 0.10 were fitted in the multivariate
Jung IY et al. Journal of the International AIDS Society 2019, 22:e25219
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25219/full | https://doi.org/10.1002/jia2.25219
2
model using backward stepwise selection process. Covariates
with p < 0.05 in the multivariate model were considered sig-
nificant. A sensitivity analysis was performed by including age
as a time-updated covariate, and adjusting for age, sex and
CD4 cell count in the final multivariate model.
Ethics approvals for TAHOD were obtained from the
respective local ethics committees of all participating sites, the
data management and biostatistical centre at the Kirby Insti-
tute (The University of New South Wales (UNSW) Human
Research Ethics Committee), and the coordinating centre at
TREAT Asia/amfAR. Written informed consent was sought in
TAHOD if required by a site’s local institutional review board.
All TAHOD data transfers are anonymized prior to submission
to the Kirby Institute. Ethics approval for AHOD was obtained
from the respective local ethics committees of all participating
sites and the UNSW Human Research Ethics Committee; writ-
ten informed consent was obtained from all participants. All
data management and statistical analyses were performed
using SAS software version 9.4 (SAS Institute Inc., Cary, NC,
USA) and Stata software version 14.2 (Stata Corp., College
Station, TX, USA).
3 | RESULTS
A total of 10,386 patients who had initiated cART and were
in follow-up between years 1999 and 2017 were included in
the study. With a median follow-up time of 6.0 years, 522
patients (155 from AHOD, 208 from TAHOD-high and 159
from TAHOD-low) experienced AIDS or non-AIDS mortality:
187 died from AIDS-related (incidence rate of 0.28 per 100
person-years (PYS)) and 335 died from non-AIDS–related
causes (0.51/100 PYS) (Table 1). In AHOD, the mortality
rate for AIDS-related death was 0.15/100 PYS and for
non-AIDS–related death it was 0.66/100 PYS, with a median
follow-up time of 6.3 years. The mortality rates for TAHOD-
high were 0.29/100 PYS for AIDS and 0.42/100 PYS for non-
AIDS deaths with a median follow-up of 7.1 years, and for
TAHOD-low the mortality rate was 0.40/100 PYS for AIDS
and 0.49/100 PYS for non-AIDS with a median follow-up of
5.5 years.
Of the 522 patients who died, the median age in the
TAHOD-low group was 34 years [interquartile range (IQR) 29
to 40], 41 years [IQR 34 to 51] in the TAHOD-high group
and 42 years [IQR 35 to 53] in AHOD. Ninety-five per cent
of patients in AHOD were men compared with 81% and 75%
in TAHOD-high and TAHOD-low income groups respectively.
Heterosexual contact was the primary route of HIV exposure
in TAHOD-high and TAHOD-low income sites (67%), whereas
men who have sex with men (MSM) was the most common
HIV exposure in the AHOD sites (70%). Median baseline CD4
cell counts were 61 cells/lL [IQR 20 to 154] in the TAHOD-
low group, 59 cells/lL [IQR 19 to 164] in the TAHOD-high
group and 210 cells/lL [IQR 87 to 350] in AHOD. Baseline
HIV RNA were 190,000 copies/mL [IQR 85,138 to 480,000]
in the TAHOD-low group, 140,000 copies/mL [IQR 47,650 to
450,000] in the TAHOD-high group and 110,000 copies/mL
[IQR 25,228 to 460,000] in AHOD. (Table 2)
Figure 1 demonstrates the proportions of AIDS-related,
non-AIDS–related and unknown causes of mortality among
those who died. The proportions of AIDS, non-AIDS and
unknown causes of death did not differ significantly across
year groups before 2007, 2008 to 2012 and 2013 to 2017 in
the TAHOD-low cohort (p = 0.196). In contrast, the TAHOD-
high and AHOD cohorts demonstrated a significant difference
in the proportions of AIDS, non-AIDS and unknown causes of
deaths over all year groups (TAHOD-high: p = 0.025; AHOD:
p < 0.001). Figure 2 shows a plot of mortality rates for
Table 1. AIDS and non-AIDS causes of death in low and high income settings in the TREAT Asia HIV Observational Database and
AHOD cohortsa
TAHOD,
low income (N)
TAHOD,
high income (N)
AHOD,
high income (N) All patients
Incidence rate (/100 PYS)
(follow-up time of 66,250 years)
Total patients in database 3240 4429 2717 10,386
Causes of death categoryb
AIDS related 72 86 29 187 0.28
Non-AIDS related 87 122 126 335 0.51
Cardiovascular disease 10 12 19 41 0.06
Cancer 2 19 37 58 0.09
Liver disease 9 17 14 40 0.06
Accidental/overdose/violence 9 14 11 34 0.05
Infectious disease 11 13 6 30 0.05
Other 13 10 9 32 0.05
Unknown 33 37 30 100 0.15
Total 159 208 155 522 0.79
AHOD, Australian HIV Observational Database; TAHOD, TREAT Asia HIV Observational Database.
aCohorts were grouped as AHOD (all high-income sites), TAHOD-high (high/upper-middle income countries) and TAHOD-low (low-middle/low income
countries). TAHOD sites were split into high/upper-middle income and low-middle/low income settings based on World Bank classifications. bCauses
of death were based on review of the standardized Cause of Death (CoDe) form designed by the Data collection on Adverse events of Anti-HIV Drugs
(D:A:D) group.
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Figure 1. Proportions of AIDS and non-AIDS mortality among those who have died.
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Figure 2. Mortality rates for different causes of death.
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Table 3. Factors associated with AIDS mortality in the TREAT Asia HIV Observational Database and AHOD cohortsa
No. of
patients
Follow-up
(years)
No. of
deaths
Incidence
rate (/100
PYS)
Univariate Multivariate
SHR (95% CI) p-value aSHR (95% CI) p-value
Total 10385 66250 187 0.28
Age (years) 0.116
≤30 3011 17,628 49 0.28 1
31 to 40 4239 27,915 70 0.25 0.98 (0.68, 1.41) 0.905
41 to 50 2116 14,302 40 0.28 1.11 (0.73, 1.69) 0.621
51+ 1020 6405 28 0.44 1.65 (1.03, 2.62) 0.037
Sex 0.357
Male 7842 50,749 137 0.27 1
Female 2544 15,501 50 0.32 1.16 (0.84 to 1.61) 0.357
HIV mode of exposure <0.001
Heterosexual contact 5366 33,915 114 0.34 1
MSM 3561 24,134 36 0.15 0.47 (0.32, 0.68) <0.001
Injecting drug use 764 3940 22 0.56 1.42 (0.90, 2.24) 0.134
Blood products 93 450 3 0.67 1.55 (0.49, 4.90) 0.453
Bisexual 140 901 4 0.44 1.31 (0.48, 3.55) 0.601
Other/unknown 462 2908 8 0.28 0.81 (0.40, 1.66) 0.564
CD4 (cells/lL) <0.001 <0.001
≤100 - 2215 102 4.60 1 1
101 to 200 - 4726 39 0.83 0.23 (0.16, 0.34) <0.001 0.31 (0.21, 0.46) <0.001
>200 - 58,513 36 0.06 0.03 (0.02, 0.04) <0.001 0.04 (0.03, 0.07) <0.001
Missing - 795 10 1.26
Viral load (copies/mL) <0.001 0.019
≤400 - 50,977 51 0.10 1 1
401 to 10,000 - 2469 12 0.49 3.42 (1.79, 6.52) <0.001 1.71 (0.87, 3.34) 0.118
≥100,001 - 4489 69 1.54 8.66 (5.84, 12.84) <0.001 1.95 (1.22, 3.13) 0.006
Missing - 8314 55 0.66
HBV co-infection 0.6085
Negative 7457 49,623 120 0.24 1
Positive 705 4421 13 0.29 1.16 (0.65, 2.06) 0.608
Missing 2224 12,206 54 0.44
HCV co-infection 0.027
Negative 6892 46,347 111 0.24 1
Positive 1110 6525 28 0.43 1.6 (1.05, 2.42) 0.027
Missing 2384 13,377 48 0.36
Diabetesb 0.014 0.012
No - 39,723 70 0.18 1 1
Yes - 1904 8 0.42 2.52 (1.21, 5.26) 0.014 2.56 (1.23, 5.33) 0.012
Missing - 24,623 109 0.44
BMI groups <0.001 <0.001
Underweight (<18.5) - 4364 66 1.51 5.98 (4.24, 8.44) <0.001 3.33 (2.31, 4.81) <0.001
Normal range (18.5 to 24.9) - 31,289 65 0.21 1 1
Overweight (≥25) - 12,168 2 0.02 0.09 (0.02, 0.37) 0.001 0.13 (0.03, 0.54) 0.005
Missing - 18,429 54 0.29
Cohort groups <0.001 0.834
TAHOD-low 3240 17,833 72 0.40 1 1
TAHOD-high 4429 29,242 86 0.29 0.82 (0.60, 1.13) 0.228 0.99 (0.68, 1.44) 0.953
AHOD 2717 19,175 29 0.15 0.44 (0.29, 0.68) <0.001 1.15 (0.64, 2.07) 0.629
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different causes of death across calendar years of follow-up.
While AIDS mortality in TAHOD-low and AHOD cohorts
decreased with statistical significance across all year groups
(TAHOD-low: p = 0.001; AHOD: p < 0.001), the decrease
across all year groups in TAHOD-high cohort was not signifi-
cant (TAHOD-high: p = 0.169). Non-AIDS mortality decreased
with statistical significance across all year groups in all cohorts
(TAHOD-low: p = 0.010; TAHOD-high: p = 0.034; AHOD:
p = 0.027). Non-AIDS mortality decreased at a slower rate
compared to AIDS-related deaths in TAHOD-high (p = 0.039)
and AHOD (p = 0.035) cohorts. In the TAHOD-low cohort,
the rate of decrease between the incidence of AIDS mortality
and non-AIDS mortality was not significant (p = 0.071). A
greater decrease in the incidence of non-AIDS mortality was
shown in AHOD compared to TAHOD-high (p = 0.009) and
TAHOD-low (p = 0.026) cohorts.
The incidence rate of AIDS-related mortality during follow-
up was 0.28/100 PYS (Table 3). Univariate analysis
demonstrated that mode of HIV exposure (p < 0.001), HCV
co-infection (p = 0.027), cohort group (p < 0.001), diabetes
(p = 0.014), BMI, CD4, RNA and calendar year (all p < 0.001)
were associated with AIDS-related mortality. In multivariate
analysis adjusting for cohort groups, factors associated with
AIDS-related mortality were higher viral load (HIV RNA
≥100,000 copies/ml) compared to HIV RNA ≤400 copies/mL
(aSHR = 1.95, 95% CI 1.22 to 3.13, p = 0.006); and high
blood glucose (aSHR = 2.56, 95% CI 1.23 to 5.33, p = 0.012).
Factors showing protective effects were CD4 count
>200 cells/lL (aSHR = 0.04, 95% CI 0.03 to 0.07, p < 0.001)
compared to CD4 ≤ 100 cells/lL; and higher BMI (over-
weight) patients (aSHR = 0.13, 95% CI 0.03 to 0.54,
p < 0.005) compared to patients who were in the normal BMI
range of 18.5 to 24.9. Calendar year was not statistically sig-
nificant in the multivariate model; however, incidence rates of
AIDS-related deaths decreased from 0.51/100 PYS to 0.09/
100 PYS in year groups from 2003 to 2017.
The incidence rate of non-AIDs–related mortality during fol-
low-up was 0.51 per 100 PYS (Table 4). Factors associated
with non-AIDS mortality in the multivariate analysis were:
older age (31 to 40 years: aSHR = 1.40, 95% CI 1.02 to 1.93,
p = 0.039; 41 to 50 years: aSHR = 1.58, 95% CI 1.10 to
2.27, p = 0.013; and >50 years: aSHR = 4.43, 95% CI 3.15 to
6.25, p < 0.001) compared to age ≤30 years; HBV co-infec-
tion (aSHR = 1.87, 95% CI 1.32 to 2.65, p < 0.001); HCV
co-infection (aSHR = 1.96, 95% CI 1.44 to 2.67, p < 0.001);
high blood glucose (aSHR = 1.77, 95% CI 1.09 to 2.86,
p = 0.021); and AHOD cohort (aSHR = 1.72, 95% CI 1.20 to
2.46, p = 0.003) compared to TAHOD-low. Non-AIDS mortal-
ity was less likely in females (aSHR = 0.5, 95% CI 0.35 to
0.70, p < 0.001); higher BMI (overweight: aSHR = 0.69, 95%
CI 0.47 to 1.01, p < 0.054) compared to normal weight range
(BMI of 18.5 to 24.9); and later calendar years of follow-up
(2008 to 2012: aSHR = 0.72, 95% CI 0.54 to 0.96, p = 0.027;
2013 to 2017: aSHR = 0.64, 95% CI 0.47 to 0.87, p = 0.004)
compared to year group 2003 to 2007. Higher CD4 count
(101 to 200 cells/lL: aSHR = 0.61, 95% CI 0.42 to 0.90,
p = 0.011; >200 cells/lL: aSHR = 0.23, 95% CI 0.17 to 0.33,
p < 0.001) compared to CD4 ≤ 100 cells/lL was also associ-
ated with lower non-AIDS mortality. However, since the multi-
variable models were adjusted for time-updated CD4 count
and viral load, changes over time in the rate of non-AIDS mor-
tality are not entirely explained by CD4 count and viral load.
Tables S1 and S2 show that by including time-updated age,
sex and CD4 in the final multivariate model, there was a simi-
lar increasing trend in the hazard for mortality with increasing
age, which has now shown significant associations with both
AIDS and non-AIDS mortality. Other risk factors and their
effects are similar to those observed in the main analyses.
4 | DISCUSSION
In our cross-regional observational cohorts who received
cART, the overall incidence rate of mortality over a median
follow-up time of 6.0 years was 0.28/100 PYS from AIDS-
related and 0.51/100 PYS from non-AIDS–related causes.
Moreover, incidence rates for AIDS-related and non-AIDS–
related mortality have decreased over the years with the
AHOD cohort showing higher hazard for non-AIDS deaths
compared to TAHOD-low sites.
With the introduction of cART, AIDS-related death has
decreased followed by an increase in non-AIDS death [4].
Table 3. (Continued)
No. of
patients
Follow-up
(years)
No. of
deaths
Incidence
rate (/100
PYS)
Univariate Multivariate
SHR (95% CI) p-value aSHR (95% CI) p-value
Calendar year <0.001
≤2002 - 2046 8 0.39 0.58 (0.28, 1.21) 0.148
2003 to 2007 - 11,006 56 0.51 1
2008 to 2012 - 25,968 98 0.38 0.87 (0.62, 1.21) 0.414
2013 to 2017 - 27,230 25 0.09 0.34 (0.21, 0.54) <0.001
Global p-values were calculated by excluding the missing category. AHOD, Australian HIV Observational Database; aSHR, adjusted sub-hazard
ratio; BMI, body mass index; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; MSM, Men who have sex with men; PYS,
person-years; SHR, sub-hazard ratio; TAHOD, TREAT Asia HIV Observational Database.
aCohorts were grouped as AHOD (all high-income sites), TAHOD-high (high/upper-middle income countries) and TAHOD-low (low-middle/low
income countries). TAHOD sites were split into high/upper-middle income and low-middle/low income settings based on World Bank classifications.
Time-fixed covariates: Age, Sex, HIV mode of exposure, HBV co-infection, HCV co-infection, Cohort Groups; time-updated covariates: CD4, Viral Load,
Diabetes, BMI Groups and Calendar year. bDiabetes was defined as documentation of one fasting blood glucose measurement ≥7 mmol/L.
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Table 4. Factors associated with non-AIDS mortality in the TREAT Asia HIV Observational Database and AHODa
No.
patients
Follow-up
(years)
No. of
deaths
Incidence rate
(/100 PYS)
Univariate Multivariate
SHR (95% CI) p-value aSHR (95% CI) p-value
Total 10,385 66,250 335 0.51
Age (years) <0.001 <0.001
≤30 3011 17,628 59 0.33 1 1
31 to 40 4239 27,915 117 0.42 1.31 (0.96, 1.79) 0.091 1.40 (1.02, 1.93) 0.039
41 to 50 2116 14,302 68 0.48 1.51 (1.06, 2.14) 0.021 1.58 (1.10, 2.27) 0.013
51+ 1020 6405 91 1.42 4.39 (3.17, 6.08) <0.001 4.43 (3.15, 6.25) <0.001
Sex <0.001 <0.001
Male 7842 50,749 299 0.59 1 1
Female 2544 15,501 36 0.23 0.40 (0.28, 0.57) <0.001 0.50 (0.35, 0.70) <0.001
HIV mode of exposure 0.005
Heterosexual contact 5366 33,915 150 0.44 1
MSM 3561 24,134 121 0.50 1.13 (0.89, 1.44) 0.298
Injecting drug use 764 3940 39 0.99 1.99 (1.40, 2.83) <0.001
Blood products 93 450 5 1.11 1.98 (0.82, 4.83) 0.131
Bisexual 140 901 6 0.67 1.52 (0.67, 3.46) 0.313
Other/unknown 462 2908 14 0.48 1.06 (0.61, 1.84) 0.826
CD4 (cells/lL) <0.001 <0.001
≤100 - 2215 63 2.84 1 1
101 to 200 - 4726 57 1.21 0.57 (0.40, 0.83) 0.003 0.61 (0.42, 0.90) 0.011
>200 - 58,513 204 0.35 0.20 (0.15, 0.26) <0.001 0.23 (0.17, 0.33) <0.001
Missing - 795 11 1.38
Viral load (copies/mL) <0.001
≤400 - 50,977 204 0.40 1
401 to 10,000 - 2469 15 0.61 1.31 (0.77, 2.22) 0.313
≥100,001 - 4489 57 1.27 2.42 (1.78, 3.29) <0.001
Missing - 8314 59 0.71
HBV co-infection <0.001 <0.001
Negative 7457 49,623 230 0.46 1 1
Positive 705 4421 37 0.84 1.80 (1.27, 2.54) 0.001 1.87 (1.32, 2.65) <0.001
Missing 2224 12,206 68 0.56
HCV co-infection <0.001 <0.001
Negative 6892 46,347 200 0.43 1 1
Positive 1110 6525 63 0.97 2.08 (1.57, 2.76) <0.001 1.96 (1.44, 2.67) <0.001
Missing 2384 13,377 72 0.54
Diabetesb <0.001 0.021
No - 39,723 164 0.41 1 1
Yes - 1904 19 1 2.44 (1.51, 3.92) <0.001 1.77 (1.09, 2.86) 0.021
Missing - 24,623 152 0.62
BMI groups <0.001 <0.001
Underweight (<18.5) - 4364 56 1.28 2.69 (1.96, 3.69) <0.001 2.21 (1.56, 3.12) <0.001
Normal range (18.5 to 24.9) - 31,289 127 0.41 1 1
Overweight (≥25) - 12,168 36 0.30 0.75 (0.52, 1.09) 0.135 0.69 (0.47, 1.01) 0.054
Missing - 18,429 116 0.63
Cohort groups 0.003 0.001
TAHOD-low 3240 17,833 87 0.49 1 1
TAHOD-high 4429 29,242 122 0.42 0.89 (0.68, 1.18) 0.421 0.99 (0.73, 1.34) 0.936
AHOD 2717 19,175 126 0.66 1.35 (1.03, 1.78) 0.029 1.72 (1.20, 2.46) 0.003
Calendar year <0.001 0.028
≤2002 - 2046 13 0.64 0.77 (0.43, 1.39) 0.39 0.66 (0.36, 1.23) 0.194
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According to the D:A:D multicohort collaboration data, the
mortality rate of all-cause death was 17.5/1000 PYS in 1999
to 2000 and decreased to 9.1/1000 PYS in 2009 to 2011 [1].
AIDS-related deaths demonstrated similar decreases in death
rates over the same period from 5.9/1000 PYS to 2.0/1000
PYS [1]. In our study, incidence rates of AIDS-related deaths
decreased from 0.51/100 PYS to 0.09/100 PYS from year
groups 2003 to 2007 to 2013 to 2017. AIDS-related COD
was the most common COD in the TAHOD cohort in year
group ≤2007, and over the years there was a decrease in the
overall incidence of AIDS deaths for all cohorts. These findings
are thought to be associated with the introduction of effective
cART in resource-limited settings, which slows the decline of
CD4 cell counts, extending the time to AIDS-related death
and the total number of AIDS deaths itself [3,16].
In a Swiss HIV cohort study, AIDS-related death was high-
est in 1992 (11.0/100 PYS, 95% CI 9.94 to 12.1) and
decreased to 0.211/100 PYS (95% CI 0.122 to 0.363) in
2010 [6]. Non-AIDS–related mortality decreased from 1.74/
100 PYS (95% CI 1.36 to 2.23) in 1993 to 0.86/100 PYS
(95% CI 0.657 to 1.13) in 2010 [6]. The results of our
study also demonstrated a declining trend in non-AIDS
deaths in the later calendar years. Additionally, we found
that there has been an increase in the proportion of
unknown deaths recorded in the AHOD cohort. This
increase in unknown deaths in AHOD was due to delay in
reporting of the causes of death by the site. Mortality rates
for AIDS and non-AIDS causes of death have declined over
the years, with the incidence rate of non-AIDS–related death
remaining high in AHOD, but declining, compared to other
causes of death. Overall, there are higher incidences of non-
AIDS deaths than AIDS-related mortality in later years in
the Asia-Pacific region, similar to those demonstrated in
other regions [1,3].
HIV-infected patients are prone to increased risk of cancer,
and an estimated 30% to 40% of patients will develop cancer
during their lifetime [17]. According to the D:A:D multicohort
collaboration data, the incidence of non-AIDS cancers
increased from 1.6/1000 PYS (1999 to 2000) to 2.1/1000
PYS (2009 to 2011) [1]. As people with HIV have a longer
lifespan with potent cART, more patients develop malignan-
cies including cancers not associated with AIDS [18,19], and
this might also explain the higher proportion of non-AIDS
deaths found in our cohorts. However, in this study, mortality
rates for non-AIDS–related malignancies decreased from
0.16/100 PYS in year groups before 2007 to 0.07/100 PYS
in year groups 2013 to 2017. Early treatment due to aggres-
sive screening may be accountable for the decrease in non-
AIDS malignancy mortality. Moreover, more detection of can-
cer due to aggressive screening in the AHOD cohort may be
the reason for the higher risk of non-AIDS–related deaths in
the AHOD cohort. The number of cardiovascular–related
deaths was also higher in the AHOD cohort. Although there
were no differences between cohorts for AIDS-related mor-
tality, the AHOD cohort was at higher risk of non-AIDS mor-
tality compared to both TAHOD cohorts with almost twice
the hazard of non-AIDS mortality compared to TAHOD-low.
The non-AIDS mortality highlights the importance for
healthcare professionals to provide more comprehensive
healthcare that includes screening for malignancy or
cardiovascular disease.
Cardiovascular events associated with lower CD4 cell
counts were suggested in both the Strategies for Management
of Antiretroviral Therapy (SMART) and D:A:D studies [20,21].
Furthermore, immunodeficiency, identified by lower CD4 cell
counts, was also strongly associated with liver-related non-
AIDS death [22]. In a prospective cohort study of HIV-
infected patients diagnosed at the age of 50 years or more,
the baseline CD4 cell count was lower and presented shorter
survival [23]. Moreover, continuing improvements in CD4 cell
count over time were attributable to the reduction in AIDS-
related deaths [1]. Our findings are similar to results of these
studies, demonstrating lower CD4 cell counts and older age
as independent risk factors for both AIDS and non-AIDS mor-
tality. Our study was also comparable to studies conducted
throughout South America and the Caribbean, which have
shown that low BMI and low haemoglobin were predictive of
mortality, especially in the early phases of cART initiation [24].
Moreover, one prospective cohort study which followed up
1119 HIV patients for a median number of 8.2 years demon-
strated that HIV-infected persons with food insecurity, catego-
rized by low BMI, were about two times more likely to
experience mortality [25]. In our study, low BMI categorized
as underweight was also a risk factor for AIDS and non-AIDS
mortality, putting emphasis on the need to incorporate nutri-
tional support in HIV treatment programs.
Table 4. (Continued)
No.
patients
Follow-up
(years)
No. of
deaths
Incidence rate
(/100 PYS)
Univariate Multivariate
SHR (95% CI) p-value aSHR (95% CI) p-value
2003 to 2007 - 11,006 86 0.78 1 1
2008 to 2012 - 25,968 136 0.52 0.68 (0.52, 0.89) 0.006 0.72 (0.54, 0.96) 0.027
2013 to 2017 - 27,230 100 0.37 0.50 (0.37, 0.67) <0.001 0.64 (0.47, 0.87) 0.004
Global p-values were calculated by excluding the missing category. AHOD, Australian HIV Observational Database; aSHR, adjusted sub-hazard
ratio; BMI, body mass index; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; MSM, Men who have sex with men; No.,
number; PYS, person-years; SHR, sub-hazard ratio; TAHOD, TREAT Asia HIV Observational Database.
aCohorts were grouped as AHOD (all high-income sites), TAHOD-high (high/upper-middle income countries) and TAHOD-low (low-middle/low
income countries). TAHOD sites were split into high/upper-middle income and low-middle/low income settings based on World Bank classifications.
Time-fixed covariates: age, sex, HIV mode of exposure, HBV co-infection, HCV co-infection, cohort groups; time-updated covariates: CD4, viral load,
diabetes, BMI groups and calendar year. bDiabetes was defined as documentation of one fasting blood glucose measurement ≥7 mmol/L.
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There are several limitations to our study. Information on
patient adherence data is not collected in AHOD and it is pos-
sible that poor patient compliance or adherence may have
been a reason for AIDS death. The delay in reporting in the
causes of death in AHOD may lead to incomplete COD ascer-
tainment and underestimation of the AIDS and non-AIDS
causes of death. However, the majority of the unknown causes
of death would be traced at a later date. While TAHOD rep-
resents a primarily urban referral patient population, crossing
from low to high country income categories, it is less repre-
sentative of national-level data. There is also the risk of
unascertained mortality among those with LTFU.
5 | CONCLUSIONS
We observed that the rates of AIDS-related and non-AIDS-
related mortality in our Asia-Pacific cohorts have decreased
over the past years. Factors associated with increased risk of
AIDS-related mortality were higher viral load, high blood glu-
cose, low CD4 cell count and low BMI. Older age, hepatitis B
and C co-infection, high blood glucose, low CD4 cell count
and BMI were associated with increased non-AIDS death.
Blood glucose levels, CD4 cell count and being underweight
were risk factors for both categories of deaths. The higher
risk for non-AIDS–associated deaths in the AHOD cohort
compared to the lower-middle income setting in TAHOD may
be related to older age and higher per cent of reporting num-
ber of deaths. The slower rate in the decline of non-AIDS
deaths and the higher proportions of non-AIDS deaths still
persisting over AIDS-related deaths demonstrate that longer
lifespans contribute to increased risk of developing cancers
and other conditions more common with older age, resulting
in more deaths from non-AIDS causes.
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